HeartBeam Establishes Scientific Advisory Board, Names Chair

There is a new leadership team in place at HeartBeam Inc. 

The company has established a Scientific Advisory Board (SAB) to provide scientific guidance and insight to its medical studies, research, and products. World-renowned cardiologist C. Michael Gibson, MS, M.D., is chairing the governing body.
 
Gibson is an interventional cardiologist, cardiovascular researcher, and educator who pioneered understanding of the “open artery hypothesis” as well as understanding of the importance of restoring flow downstream in the capillary bed in the “open microvasculature hypothesis” in a heart attack. He’s been a leading investigator in trials of thrombolytic agents, glycoprotein 2b3a inhibitor agents, thienopyridines, factor Xa inhibitors, lipid-lowering agents and new devices. Gibson was named one of the world’s most widely published and cited scientists of past decade in 2018 – 2021 by Thomson Reuters.

“I am privileged to be appointed chair of the Scientific Advisory Board and look forward to bringing together a group of highly accomplished and experienced individuals to support HeartBeam’s technology platform,” said Gibson. “We intend to select additional SAB members who will bring expertise that will help drive the company to success in the use of its proprietary ECG telemedicine technology to help diagnose heart attacks in patients outside of a medical institution.”
 
Gibson founded and led his own Academic Research Organization (PERFUSE) for 30 years and has been the principal investigator of or led core services for more than 120 clinical trials, the results of which have been published in leading journals. Under his direction, PERFUSE created the master database that unified data from over many years of TIMI studies (TIMI 1-50) in nearly 100,000 patients and coordinated data analyses for the TIMI study group and functioned as the TIMI Data Coordinating Center. He has led phase 1-4 clinical trials, and cardiology megatrials of more than 15,000 patients which eventuate in international approval of drugs like prasugrel, rivaroxaban, and betrixaban.
 
Gibson also founded wikidoc.org and wikipatient.org, widely viewed open-source textbooks of medicine. He also founded clinicaltrialresults.org and has conducted more than 2,000 TV/video interviews. He has 440,000 followers on Twitter with millions of impressions at major meetings. 
 
“On behalf of our Board of Directors and management team, we welcome Dr. Gibson to the newly established SAB, bringing over three decades of leadership in cardiology as a researcher and one of world’s leading cardiologists,” said Branislav Vajdic, Ph.D., CEO and founder of HeartBeam. “His scientific perspective will provide value in supporting the advancement of our product development, including our ER solution for more accurate MI detection and a complete telehealth solution for remote MI monitoring.”

HeartBeam Inc. is a development stage digital healthcare company with proprietary ECG telemedicine technology that will redefine the way high risk cardiovascular patients are diagnosed in an ambulatory setting at any time and any place. Its breakthrough solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of patients with coronary artery disease at high risk of heart attack.